Bleeding with oral anticoagulant dabigatran is highly associated with occult cancers in atrial fibrillation patients.
The aim of this study was to examine cancer and bleeding in atrial fibrillation patients administered with dabigatran. This study enrolled 509 consecutive nonvalvular atrial fibrillation patients who received dabigatran. The mean administration period was 14.8 ± 15.7 months. We investigated the prevalence and new development of cancers. Further, the relation between cancer and adverse events was evaluated. In the 509 patients, major bleeding occurred in 2.6% and dyspepsia in 8.4%. Further, 16.9% patients had a history of cancer and 3.9% developed new cancers. These adverse events developed in 45% patients who developed new cancers. The cancer (hazard ratio: 6.30; p = 0.003) was a significant predictor of major bleeding. Bleeding was associated with the presence of cancer.